fasudil has been researched along with Encapsulating Peritoneal Sclerosis in 2 studies
fasudil: intracellular calcium antagonist; structure in first source
fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Peng, W | 1 |
| Zhou, Q | 1 |
| Ao, X | 1 |
| Tang, R | 1 |
| Xiao, Z | 1 |
| Washida, N | 1 |
| Wakino, S | 1 |
| Tonozuka, Y | 1 |
| Homma, K | 1 |
| Tokuyama, H | 1 |
| Hara, Y | 1 |
| Hasegawa, K | 1 |
| Minakuchi, H | 1 |
| Fujimura, K | 1 |
| Hosoya, K | 1 |
| Hayashi, K | 1 |
| Itoh, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pilot Study of Telmisartan (Micardis) For the Prevention of Acute Graft vs. Host Disease Post Allogeneic Hematopoietic Stem Cell Transplantation[NCT02338232] | 32 participants (Actual) | Interventional | 2015-07-07 | Terminated (stopped due to Lack of Accrual) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 other studies available for fasudil and Encapsulating Peritoneal Sclerosis
| Article | Year |
|---|---|
Inhibition of Rho-kinase alleviates peritoneal fibrosis and angiogenesis in a rat model of peritoneal dialysis.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Actins; Animals; Collagen Type I; Dialysis Solutions; | 2013 |
Rho-kinase inhibition ameliorates peritoneal fibrosis and angiogenesis in a rat model of peritoneal sclerosis.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amides; Animals; Anti-Infective Agents, Local; Cells, | 2011 |